Search Results
Your search for ,foR matches 32878 pages
Showing 5051 - 5100Nivolumab Plus Cabozantinib With or Without Ipilimumab in Advanced Hepatocellular Carcinoma
As reported in the Journal of Clinical Oncology by Thomas Yau, MD, and colleagues, findings in a cohort of the phase I/II CheckMate 040 trial indicated the activity of nivolumab/cabozantinib with or without ipilimumab in patients with advanced hepatocellular carcinoma. Study Details In the...
FDA Approves FoundationOne Liquid CDx as a Companion Diagnostic for a Certain Group of Tyrosine Kinase Inhibitors
On December 21, Foundation Medicine, Inc, announced that the U.S. Food and Drug Administration (FDA) approved its FoundationOne Liquid CDx as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R substitutions...
2022 San Antonio Breast Cancer Symposium Award Recipients Announced
The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an SABCS cosponsor, honored two researchers for their significant contributions to breast cancer research at the 2022 SABCS. 2022 AACR Distinguished Lectureship in Breast Cancer Research Charles ...
Phase III NORA Study: Niraparib Maintenance Shows Favorable Overall Survival Trend in Platinum-Sensitive Recurrent Ovarian Cancer
Poly (ADP-ribose) polymerase (PARP) inhibitor maintenance therapy may do more than just delay disease progression for patients with platinum-sensitive, relapsed ovarian cancer; it might also improve overall survival, according to data presented by Mansoor Raza Mirza, MD, during the December Virtual ...
Cervical Cancer Incidence and Survival by Histologic Subtype Among Racial/Ethnic Groups
In a U.S. population-based study reported in the Journal of Clinical Oncology, Cohen et al found that Black patients had the lowest incidence of cervical adenocarcinoma—but the poorest related 5-year survival and overall mortality—compared to patients with cervical adenocarcinoma in other...
2021 JADPRO Article of the Year Award Spotlights Management of Adverse Events in Immunotherapy
A team of advanced practice providers in the Department of Hematology/Oncology at Fox Chase Cancer Center have received the 2021 Article of the Year Award from the Journal of the Advanced Practitioner in Oncology (JADPRO). This award is given to one article each year that demonstrates an...
Sodium Thiosulfate to Reduce the Risk of Cisplatin-Related Ototoxicity in Pediatric Patients With Localized Solid Tumors
On September 20, 2022, sodium thiosulfate was approved to reduce the risk of ototoxicity associated with cisplatin in pediatric patients (aged ≥ 1 month) with localized, nonmetastatic solid tumors.1 Supporting Efficacy Data Approval was based on findings in the multicenter open-label SIOPEL 6...
MD Anderson and WHO Establish a New International Collaboration to Reduce the Global Burden of Women’s Cancers
The University of Texas MD Anderson Cancer Center and the World Health Organization (WHO) recently announced a formal agreement to establish a new international collaboration concentrated on reducing the global burden of women’s cancers. The agreement builds on years of collaboration between the...
Long-Term Follow-up of High-Dose Cytarabine and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma
Long-term results of the phase III Mantle Cell Lymphoma Younger Trial were reported in the Journal of Clinical Oncology by Hermine et al. They showed a maintained advantage in time to treatment failure and an overall survival advantage with R-CHOP/R-DHAP (alternating rituximab plus...
Ivosidenib/Azacitidine for Newly Diagnosed IDH1-Mutant Acute Myeloid Leukemia in Patients Aged 75 or Older or With Comorbidities
On May 25, 2022, ivosidenib was approved for use in combination with azacitidine for newly diagnosed acute myeloid leukemia with a susceptible IDH1 mutation, as detected by a U.S. Food and Drug Administration–approved test, in patients aged 75 or older or in those who have comorbidities precluding...
Cedars-Sinai Cancer Leaders Assume New Roles
Lali Medina-Kauwe, PhD, former Co-Leader of the Cancer Biology Program in Cedars-Sinai Cancer, assumed a new role as Associate Director for Basic Research. The Cancer Biology Program will now be led by Dolores Di Vizio, MD, PhD, Professor of Biomedical Sciences, Pathology and Laboratory Medicine in ...
How Do You Move Forward With a Life You Didn’t Choose After a Cancer Diagnosis?
“I was in bed in the surgical wing of Duke University Hospital when the doctor popped his head in and smiled apologetically before flicking on the fluorescent lights. It was 4:00 AM, the end of my second night in the hospital, but nobody sleeps in the conventional sense,” writes Kate Bowler in the...
Fox Chase Receives $6 Million Grant as Founding Member of New NCI Prevention Initiative
Fox Chase Cancer Center was recently awarded a grant for $6 million over the course of 5 years to develop a new Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT). The new National Cancer Institute (NCI) program was created to establish a pipeline for the discovery of new...
New Approaches Still Needed to Treat Patients With Cancer Who Have Serious Mental Illness
Although mandates by ASCO and the American Cancer Society to meet the needs of underserved populations have drawn much-needed awareness to the issue, patients with cancer who experience bipolar disorder, schizophrenia, and other debilitating mental illnesses continue to experience significantly...
Interim Analysis of Overall Survival in the monarchE Trial
As reported in The Lancet Oncology by Stephen R.D. Johnston, MD, PhD, and colleagues, an interim analysis of overall survival in the phase III monarchE trial has shown no significant benefit with the addition of adjuvant abemaciclib to endocrine therapy in patients with hormone receptor–positive,...
Risk Model for Predicting the Development of Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Nyberg et al developed the risk model CanRisk-Prostate for predicting the development of prostate cancer based on age, detailed cancer family history, moderate- to high-risk pathogenic variants, and a polygenic score for common low-risk...
FDA Approves Pafolacianine to Aid Lung Cancer Surgery
The U.S. Food and Drug Administration (FDA) has approved the targeted imaging agent pafolacianine (Cytalux) for use in lung cancer surgery. This injectable diagnostic binds to cancerous tissue and glows when stimulated by near-infrared light, making it easier for surgeons to remove tumors...
A Serendipitous Ride Along a Highway May Have Saved My Life
In 2017, I noticed a roadside billboard touting the benefits of low-dose computed tomography (CT) imaging for lung cancer screening. The message probably saved my life. The public service campaign, called Saved by the Scan from the American Lung Association, included an Internet address where I...
Sidney Kimmel Cancer Center Establishes Geriatric Oncology Center of Excellence at Jefferson Health
Jefferson Health’s Sidney Kimmel Cancer Center (SKCC) recently launched the Geriatric Oncology Center of Excellence to address the needs of a growing patient population through innovative research and care delivery methods via a multidisciplinary approach. The center identifies and removes barriers ...
Traditional Chinese Medicine Herbal Formula Shen Ling Bai Zhu San for Chronic Diarrhea
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on ...
Robin Zon, MD, FACP, FASCO, Elected ASCO President for 2024–2025 Term
ASCO has elected Robin Zon, MD, FACP, FASCO, a long-time member and volunteer, to lead as its President beginning in June 2024. Dr. Zon will take office as President-Elect immediately following the ASCO Annual Business Meeting in Chicago on June 5, 2023. Five additional members were also elected to ...
Risk of Adverse Side Effects From Cancer Immunotherapy May Be Higher in Patients With Certain Inherited Genetic Variations
Even as they’ve revolutionized cancer treatment, immune checkpoint inhibitors have been shown to produce a range of adverse immune-related side effects. Researchers have now identified inherited genetic variations that may place patients at high risk for complications when undergoing treatment with ...
From Immigrant Roots to a Budding Career in Oncology, Gladys Magaly Rodriguez, MD, Aims to Advance Health Equity in Vulnerable Populations
Gladys Magaly Rodriguez, MD, was born in Piedras Negras, Mexico, a city situated along the banks of the Rio Grande. At age 6, her family immigrated to Eagle Pass, Texas, a border town of some 30,000 people that is predominantly Latinx and Spanish speaking. “Even though I lived and attended school...
Tremelimumab Combined With Durvalumab and Platinum-Based Chemotherapy in Metastatic NSCLC
On November 10, 2022, tremelimu-mab in combination with durvalumab and platinum-based chemotherapy was approved for patients with metastatic non–small cell lung cancer (NSCLC) with no sensitizing EGFR mutation or ALK genomic tumor aberrations.1 Supporting Efficacy Data Approval was supported by...
Alex Herrera, MD, Finds a Path From the Baseball Fields of Miami to a Leadership Role at City of Hope
Lymphoma expert Alex Herrera, MD, was born in Miami; his parents were just 19 years old when he was born. Dr. Herrera’s father was born in Puerto Rico to Cuban and Ecuadorian parents. His mother was born in Cuba and came to the United States via Operation Peter Pan, the clandestine program that...
Understanding the Health Provisions in the Inflation Reduction Act and Their Implications for Oncology Care
The Inflation Reduction Act of 2022, signed into law on August 16, 2022, contains several important provisions regarding health care and drug pricing.1 In this article, I provide an overview of the legislation’s implications for oncology care, focusing on its provisions concerning drug price...
Chemotherapy Dose Intensity and Survival in Older Women With Early-Stage Breast Cancer: Analysis From the HOPE Trial
In an analysis from the HOPE trial reported in the Journal of Clinical Oncology, Mina S. Sedrak, MD, MS, and colleagues found that approximately one-fifth of older women with early-stage breast cancer received a relative dose intensity (RDI) of neoadjuvant/adjuvant chemotherapy that was below...
Financial Burden for Blood or Marrow Transplantation Survivors During the COVID-19 Pandemic
In an analysis from the BMT Survivor Study (BMTSS) reported in the Journal of Clinical Oncology, Smita Bhatia, MD, MPH, and colleagues found that survivors of blood or marrow transplantation (BMT) were more likely to have high out-of-pocket medical costs vs comparator siblings during the COVID-19...
Prostate Cancer Screening With MRI-Targeted vs MRI-Targeted and Systemic Biopsy
In a Swedish study (GÖTEBORG-2) reported in The New England Journal of Medicine, Hugosson et al found that magnetic resonance imaging (MRI)-targeted prostate biopsy was associated with a lower risk of overdiagnosis of clinically insignificant prostate cancer compared with MRI-targeted and...
Indiana University Names Music Therapy Researcher Sheri Robb, PhD, as New Walther Professor of Supportive Oncology
Indiana University (IU) School of Medicine has named Sheri Robb, PhD, a Walther Professor of Supportive Oncology. This is one of five endowed positions to develop a supportive oncology program that encompasses research and patient care. Dr. Robb is a nationally renowned music therapy researcher,...
Brentuximab Vedotin Combined With Chemotherapy in Pediatric Classical Hodgkin Lymphoma
On November 10, 2022, brentuximab vedotin was approved for use in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients aged ≥ 2 years with previously untreated high-risk classical Hodgkin lymphoma.1 Supporting Efficacy Data Approval was...
First-Line Nivolumab/Ipilimumab vs EXTREME Regimen in Recurrent or Metastatic Head and Neck Cancer
The final results of the phase III CheckMate 651 trial showed no significant overall survival benefit with first-line nivolumab/ipilimumab vs the EXTREME regimen (cetuximab plus cisplatin or carboplatin plus fluorouracil for up to six cycles, followed by cetuximab maintenance) in recurrent or...
FDA Approves First Gene Therapy for High-Risk Non–Muscle-Invasive Bladder Cancer
On December 16, the U.S. Food and Drug Administration (FDA) approved nadofaragene firadenovec-vncg (Adstiladrin), a nonreplicating adenoviral vector–based gene therapy indicated for the treatment of adult patients with high-risk bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive...
Study Reports Activity With Oncolytic Vaccine Plus Pembrolizumab in BCG-Unresponsive Bladder Cancer
An oncolytic therapy delivered within the urinary bladder in combination with pembrolizumab has yielded the “best results seen in the field” in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladder cancer, according to data presented during the 2022 Society for Immunotherapy of Cancer...
Adavosertib in Refractory Solid Tumors With CCNE1 Amplification
In a phase II trial reported in the Journal of Clinical Oncology, Fu et al found that the WEE1 kinase inhibitor adavosertib was active in patients with refractory solid tumors with CCNE1 amplification, with evidence of increased activity in epithelial ovarian cancer. Study Details In the trial, 30...
TIL Therapy vs Ipilimumab in Advanced Melanoma
In a Dutch-Danish phase III trial reported in The New England Journal of Medicine, Rohaan et al found that tumor-infiltrating lymphocyte (TIL) therapy prolonged progression-free survival vs ipilimumab in patients with advanced melanoma. Study Details The open-label trial included 168 patients...
Brain Cancer After CT Scans in Children and Young Adults
In a European cohort study (EPI-CT) reported in The Lancet Oncology, Hauptmann et al found an increased risk of brain cancer with increasing brain radiation dose among children and young adults who had undergone computed tomography (CT) scans. Study Details The study used pooled data from nine...
Impact of Geriatric Assessment and Management on Quality of Life and Other Outcomes in Older Patients With Cancer
In the Canadian 5C study reported in the Journal of Clinical Oncology, Puts et al found that a geriatric assessment and management intervention did not improve quality of life, unplanned health-care use, mortality, or toxicity compared with usual care in patients aged 70 years or older with cancer. ...
Study Finds That Patients With Neuroendocrine Cancer and Doctors May Agree on Treatment Goals Only Half of the Time
Researchers revealed that patients with neuroendocrine cancer overwhelmingly prioritized quality of life over living longer, according to a new study published by Li et al in JNCCN–Journal of the National Comprehensive Cancer Network. The researchers surveyed 60 patients with advanced...
Sean Khozin, MD, MPH, on Randomized Trials vs Real-World Evidence in Patients With Advanced Cancer
Sean Khozin, MD, MPH, of the Massachusetts Institute of Technology, discusses the “external validity deficits” of randomized clinical trials, which still involve only about 5% of adults with cancer, who may differ in important ways from real-world populations. Dr. Khozin describes the reasons for...
FDA Approves Updated Drug Labeling for Capecitabine Tablets Under Project Renewal
On December 14, the U.S. Food and Drug Administration (FDA) approved updated labeling for capecitabine tablets (Xeloda) under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for certain older oncology drugs to ensure information is clinically...
Impact of Adjuvant Therapy on Outcomes in Patients With Node-Negative Disease After Neoadjuvant Therapy and Resection of Pancreatic Carcinoma
In a retrospective cohort study reported in JAMA Surgery, Hammad et al found that adjuvant therapy was associated with better outcomes vs no adjuvant therapy in patients with node-negative disease after neoadjuvant therapy and resection of pancreatic carcinoma. Study Details The study used data...
Updated Subgroup Analyses From the HER2CLIMB Trial in Previously Treated Patients With HER2-Positive Breast Cancer
In updated analyses from the phase III HER2CLIMB trial reported in JAMA Oncology, Nancy U. Lin, MD, and colleagues found that the addition of tucatinib to trastuzumab and capecitabine showed improved outcomes among previously treated patients with HER2-positive breast cancer and baseline brain...
Bipartisan Comprehensive Cancer Survivorship Act Introduced
On December 14, U.S. Representative Mark DeSaulnier (D-CA), Representative Debbie Wasserman Schultz (D-FL), Senator Amy Klobuchar (D-MN), Senator Ben Cardin (D-MD), and Representative Brian Fitzpatrick (R-PA) introduced the Comprehensive Cancer Survivorship Act (CCSA)—legislation that will address...
Travel Time for Breast Cancer Screening May Remain Long for Many Patients, New Study Shows
Investigators revealed that the travel time to the nearest mammography facility may be long for a considerable proportion of patients in the United States, particularly affecting more than 50% of patients in the rural areas of 28 states, according to a new study published by Wiese et al in the...
Modakafusp Alfa May Be Effective at Treating Patients With Multiple Myeloma
The novel drug modakafusp alfa has shown early promise in combating relapsed/refractory multiple myeloma, according to new findings presented by Vogl et al at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 565). Background Modakafusp alfa is a fusion protein...
Genome Sequencing of Circulating Tumor Cells in Detection of Myeloma and Precursor Conditions
The novel MinimuMM-seq technique may make it possible to detect tumor cells in individuals at higher risk for multiple myeloma, assess the risk of disease progression in patients with myeloma, and track genetic changes in tumor cells over time from a single blood sample, according to a new study...
Jennifer R. Brown, MD, PhD, on CLL/SLL: New Findings on Zanubrutinib vs Ibrutinib for Relapsed or Refractory Disease
Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses phase III findings of the ALPINE study, which showed that zanubrutinib is more efficacious and better tolerated than ibrutinib as a treatment for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small...
Mark R. Litzow, MD, on ALL: Consolidation Therapy With Blinatumomab Improves Overall Survival
Mark R. Litzow, MD, of the Mayo Clinic, discusses phase III results from the ECOG-ACRIN E1910 Trial, which show that adding blinatumomab to consolidation chemotherapy resulted in a significantly better overall survival in adult patients aged 30 to 70 years with newly diagnosed B-lineage acute...
NCI Director Monica M. Bertagnolli, MD, FACS, FASCO, Announces Breast Cancer Diagnosis
On December 14, Monica M. FACS, Bertagnolli, MD, FASCO, Director of the National Cancer Institute (NCI), released the following statement: I was very recently diagnosed with early breast cancer. The prognosis is very favorable. The cancer is hormone receptor–positive, HER2-negative breast cancer...
